Compugen Ltd.

Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026

Compugen announced it will release third quarter 2026 financial results before U.S. markets open on Monday, November 9, 2026. Management will host a conference call the same day at 8:30 AM ET, with a live webcast and subsequent replay available on the company's website. This is a scheduling notice only; no financial results or guidance were disclosed. The company's pipeline includes COM701 in ovarian cancer, AstraZeneca-licensed rilvegostomig, and Gilead-licensed GS-0321.

•6d ago

Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference

Compugen management will participate in a fireside chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference, held virtually October 8-9, 2026. The presentation is scheduled for Thursday, October 8, 2026 at 9:30 AM ET, with a live webcast and subsequent replay available on the company's investor relations site. The release contains no new clinical or financial data; the pipeline summary reiterates COM701, rilvegostomig (licensed to AstraZeneca) and GS-0321 (licensed to Gilead).

•26d ago

Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026

Compugen will host a virtual KOL event on Monday, October 5, 2026 at 8:00 AM ET, featuring Dr. Oladapo Yeku of Harvard Medical School and Massachusetts General Hospital, to discuss COM701 and the evolving ovarian cancer treatment landscape. Dr. Yeku will preview the randomized MAIA-ovarian adaptive platform trial design of COM701, a potential first-in-class anti-PVRIG antibody in maintenance treatment for relapsed platinum-sensitive ovarian cancer, with median progression-free survival data from the interim analysis expected by Q1 2027. Compugen's Research and Discovery team will also provide an update on expanded capabilities of Unigen, its AI/ML-powered target discovery platform. The release sets a concrete clinical catalyst for the lead asset, the Q1 2027 interim PFS readout, alongside a broader pipeline that includes AstraZeneca-licensed rilvegostomig in Phase 3 trials and Gilead-licensed GS-0321 in Phase 1.

•1mo ago

Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

Compugen management will participate in a fireside chat and hold one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16 in New York City. The fireside chat is scheduled for Monday, September 14, 2026 at 3:30 PM ET, with a live webcast available on Compugen's investor relations website and a replay posted afterward. Compugen is a clinical-stage cancer immunotherapy company using its AI-powered Unigen platform; its pipeline includes COM701 in a relapsed platinum-sensitive ovarian cancer trial, rilvegostomig (PD-1/TIGIT bispecific) licensed to AstraZeneca and in Phase 3/2/1 trials, and GS-0321 licensed to Gilead and in Phase 1. The release contains no new financial, clinical, or corporate data — it is a scheduling notice ahead of potential conference commentary.

•1mo ago

Compugen Reports Second Quarter 2026 Results

Compugen reported Q2 2026 revenue of $2.6 million, doubling from $1.3 million in the prior year, driven by milestone payments from partner Gilead. Net loss narrowed slightly to $7.0 million, or $0.07 per share, while cash, cash equivalents, and investments totaled $125.3 million, providing a runway into 2029. Operationally, the MAIA-ovarian trial for COM701 remains on track for an interim analysis with median PFS data expected by Q1 2027. Partner AstraZeneca presented the first overall survival readout for rilvegostomig, showing 16.8 months in first-line biliary tract cancer, and initiated an additional Phase 3 trial. The Gilead-partnered GS-0321 Phase 1 trial is progressing as planned. The company has no debt and continues to advance its immuno-oncology pipeline leveraging its Unigen platform.

•2mo ago

Compugen to Participate in BTIG Biotechnology Conference 2026

Compugen Ltd. management will present and participate in one-on-one meetings at the virtual BTIG Biotechnology Conference 2026 scheduled for July 28-29. The company is a clinical-stage immuno-oncology firm utilizing its Unigen AI/ML platform to discover novel drug targets. Its pipeline includes COM701 in ovarian cancer trials, the AstraZeneca-partnered rilvegostomig, and the Gilead-licensed GS-0321.

•3mo ago

Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026

Compugen announced that it will release its second quarter 2026 financial results on Monday, August 3, 2026, before the U.S. markets open. Management is scheduled to host a conference call and webcast at 8:30 AM ET on the same day to review the results and provide a corporate update. Investors can access the live call via telephone or webcast, with a replay made available on the company's website shortly after the event.

•3mo ago

Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress

Compugen presented a trial-in-progress poster at the ESMO Gynaecological Cancers Congress detailing the MAIA-ovarian study of its anti-PVRIG antibody COM701. The randomized adaptive platform trial is evaluating COM701 as a maintenance therapy for patients with relapsed platinum-sensitive ovarian cancer, where no standard of care currently exists. Management expects initial data readouts from the trial by the first quarter of 2027.

•4mo ago

Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026

Compugen will present a trial-in-progress poster for its Phase 1 MAIA-ovarian study of COM701 at the ESMO Gynaecological Cancers Congress 2026. The poster, presented by Dr. Oladapo Yeku of Massachusetts General Hospital, evaluates COM701 as a maintenance treatment in relapsed platinum-sensitive ovarian cancer. The presentation is scheduled for June 18, 2026, in Copenhagen, with the poster subsequently available on Compugen's website.

•4mo ago

Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development

Compugen management will participate in a Jones Trading fireside chat on June 15, 2026, focusing on AI/ML-based drug development. The event is part of a series titled 'Mapping the Path from Target to Patient' and will be webcast live from 10:30-11:00 AM ET. No new clinical data or business developments were announced in this release; it serves as a notice of upcoming investor relations activity.

•4mo ago

Compugen Reports First Quarter 2026 Results

Compugen reported Q1 2026 revenue of $2.2 million and a net loss of $7.7 million ($0.08 per share), in line with the prior year's results. The company holds $134.9 million in cash and investments, providing a runway into 2029 without debt. Operationally, the COM701 MAIA-ovarian trial is actively enrolling with an interim analysis expected in Q1 2027, while partner AstraZeneca advances rilvegostomig across 11 Phase 3 trials.

•5mo ago

Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

Compugen Ltd. announced that it will release its first quarter 2026 financial results on Monday, May 18, 2026, prior to the market open. Management is scheduled to host a conference call and webcast at 8:30 AM ET to review the results and provide a corporate update. The company is a clinical-stage cancer immunotherapy firm with key programs including COM701 and partnered assets with AstraZeneca and Gilead.

•5mo ago